This inventor holds 2 USPTO granted patents and 6 published patent applications and 1 EPO patent. Top assignee: Merck Sharp + Dohme Corp.. Active years: 2022.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2022
Title: The Innovative Contributions of Jared K Lunceford
Introduction
Jared K Lunceford is a notable inventor based in Washington, UT (US). He has made significant contributions to the field of biotechnology, particularly in the development of gene signature biomarkers for cancer treatment. With a total of 2 patents, Lunceford's work is paving the way for advancements in personalized medicine.
Latest Patents
Lunceford's latest patents include groundbreaking technologies that focus on improving cancer therapies. One of his patents is titled "System and methods for deriving gene signature biomarkers of response to PD-1 antagonists." This patent discloses a gene expression platform that combines a set of genes correlated with response to PD-1 antagonists across multiple tumor types. It also includes a normalization gene set and outlines methods for deriving gene signature biomarkers of anti-tumor response to PD-1 antagonists. Another significant patent is "Blood-based biomarkers of tumor sensitivity to PD-1 antagonists." This disclosure describes both baseline and on-treatment blood-based gene signature biomarkers that predict tumor sensitivity to therapy with PD-1 antagonists. The on-treatment biomarkers include a PD-L1 gene signature or an interferon gamma gene signature, while the baseline gene signature biomarker comprises genes associated with the oxidative phosphorylation pathway. The patent also provides methods and kits for testing tumor samples for these biomarkers.
Career Highlights
Lunceford is currently employed at Merck Sharp & Dohme Corporation, where he continues to innovate in the field of cancer research. His work is instrumental in developing therapies that can significantly improve patient outcomes.
Collaborations
Throughout his career, Lunceford has collaborated with talented individuals such as Mark David Ayers and Andrey Loboda. These collaborations have further enhanced the impact of his research and innovations.
Conclusion
Jared K Lunceford's contributions to the field of biotechnology and cancer treatment are noteworthy. His innovative patents and ongoing work at Merck Sharp & Dohme Corporation highlight his commitment to advancing medical science.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile